Diane De Croze

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

Anne‐Sophie Hamy, Lauren Darrigues, Enora Laas et al. · PLoS ONE · 2020 · 90 citations · Full text

Medicine, Oncology, Breast Oncology +16

Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Anne‐Sophie Hamy, Hélène Bonsang‐Kitzis, Diane De Croze et al. · Clinical Cancer Research · 2019 · 67 citations

Medicine, Immunology, Oncology +17

Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Giuseppe Floris, François Richard, Anne‐Sophie Hamy et al. · JNCI Journal of the National Cancer Institute · 2020 · 48 citations · Full text

Medicine, Biostatistics, Oncology +13

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Beatriz Grandal, Clémence Evrevin, Enora Laas et al. · Cancers · 2020 · 46 citations · Full text

Life Sciences, Immunology, Oncology +15

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore

Enora Laas, Julie Labrosse, Anne‐Sophie Hamy et al. · British Journal of Cancer · 2021 · 34 citations · Full text

Medicine, Biostatistics, Oncology +17